Triangle Business Journal: Going Virtual

June 12, 2020
Claudia Christian, Senior Vice President, Clinical Operations at FHI Clinical, recently spoke with Seth Gulledge, writer for the Research Triangle Park, North Carolina-based Triangle Business Journal, about how the COVID-19 pandemic has disrupted the traditional model for clinical trials. This has prompted CROs around the Triangle to rapidly integrate virtual trial models to speed up clinical research and push COVID-19 vaccines and therapies to market.
Christian explained how at least 95 percent of FHI Clinical’s clinical trials were “either stopped or significantly slowed down” due to the pandemic, ultimately prompting a paradigm shift toward virtual trials. The rapid adoption has increased demand for the company’s services, resulting in the hiring of multiple new employees at FHI Clinical.

While fears of quality had previously slowed the transition to virtual trials, Christian noted that these fears have proven to be unfounded. 

“This has already been shifting in the industry, mostly probably driven by cost and time with the quality question mark,” she said. “But now I think we’re proving more faster than we would have before, now that the quality is there.”

FHI Clinical uses past outbreak experience to lead responses in crisis situations—from rapid study start-up to leveraging existing research networks and contributing to local health systems. Currently, FHI Clinical is supporting multiple SARS-CoV-2 studies.
For more of Christian’s interview, check out the Triangle Business Journal article.

news archive

Evaluation of baricitinib versus dexamethasone for adults hospitalized with COVID-19 in the global ACTT-4 study

September 7, 2022
The global ACTT-4 study, supported by FHI Clinical, evaluated baricitinib vs dexamethasone for adults hospitalized with COVID-19. This trial is the fourth and final stage in a series of phase 3, randomized, double-blind, placebo-controlled trials to evaluate the clinical efficacy and safety of investigational therapeutic agents in hospitalized adults with laboratory-confirmed COVID-19.

Read more »

FHI Clinical announces the closing of its acquisition of the clinical trials business of South Africa-based Triclinium Clinical Development (TCD)

February 8, 2022
FHI Clinical Inc. announces today the official closing of its acquisition of the clinical trials business of Triclinium Clinical Development Proprietary Limited (TCD), a full-service, South Africa-based CRO. With the acquisition, FHI Clinical expands its share of the infectious disease (ID) clinical development market and becomes the dominant service provider in sub-Saharan Africa.

Read more »

Share this post